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Ping Zhan1†, Qin Wang2†, Qian Qian1 and Li-Ke Yu1*Abstract
Many studies have examined the association between the XRCC3 Thr241Met gene polymorphism and lung cancer
risk in various populations, but their results have been inconsistent. To assess this relationship more precisely, a
meta-analysis was performed. The PubMed, Embase, Web of Science, and CNKI database was searched for case–
control studies published up to July 2012. Data were extracted and pooled odds ratios (OR) with 95% confidence
intervals (CI) were calculated.
Ultimately, 17 studies, comprising 4123 lung cancer cases and 5597 controls were included. Overall, for T allele
carriers (TC + TT) versus the wild-type homozygotes (CC), the pooled OR was 0.95 (95% CI = 0.87-1.04 P = 0.228 for
heterogeneity), for TT versus CC the pooled OR was 0.99 (95% CI = 0.86-1.15 P = 0.315 for heterogeneity). In the
stratified analysis by ethnicity, histological types of lung cancer and smoking status, no any significantly risks were
found for (C/T + T/T) vs C/C or T/T vs C/C. No publication bias was found by using the funnel plot and Egger's test.
Overall, there is no evidence showing a significant correlation between XRCC3 Thr241Met polymorphism and lung
cancer risk stratified analysis by ethnicity, histology and smoking status.
Keywords: XRCC3, Polymorphism, Lung cancer, Susceptibility, Meta-analysisIntroduction
Lung cancer remains the most lethal cancer worldwide,
despite improvements in diagnostic and therapeutic
techniques [1]. Its incidence has not peaked in many
parts of world, particularly in China, which has become
a major public health challenge all the world [2]. The
mechanism of lung carcinogenesis is not understood. Al-
though smoking status is the single most important fac-
tor that causes lung cancer, host factors including
genetic polymorphism, had garnered interest with regard
to the study of the tumorigenesis of lung cancer [3].
Otherwise, accumulating studies have suggested that
lung cancers occurring in never smokers have different
molecular profiles. In this way, host genetic susceptibility
is a very important factor in the development of lung
cancer, contributing to the variation in individual cancer
risk. DNA repair gene system plays a crucial role in pro-
tecting against gene mutation caused by tobacco smoke.
Recent studies have revealed that single nucleotide* Correspondence: yulike_nanjing@163.com
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reproduction in any medium, provided the orpolymorphisms (SNPs) in DNA repair genes may be the
underlying molecular mechanism of the individual vari-
ation of DNA repair capacity [4,5]. Increasing molecular
epidemiologic evidence has shown that polymorphisms
in various DNA repair genes are associated with an
increased risk of lung cancer [6,7].
The X-ray repair cross-complementing group 3
(XRCC3) belongs to a family of genes responsible for
repairing DNA double strand breaks caused by normal
metabolic processes and/or exposure to ionizing radi-
ation [8].The XRCC3 gene codes for a protein involved
in homologous recombinational repair (HRR) for double
strand breaks of DNA (DBSs) and cross-link repair in
mammalian cells [9]. During HRR, the XRCC3 protein
interacts with Rad51 protein and likely contributes to
maintain chromosome stability. A common polymorph-
ism in exon 7 of the XRCC3 gene results in an amino
acid substitution at codon 241 (Thr241Met) that may
affect the enzyme function and/or its interaction with
other proteins involved in DNA damage and repair [10].
The predominant homozygous allele, the heterozygous
allele and the homozygous rare allele of the XRCC3td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the homozygote (T/T), respectively.
Recently, many studies have investigated the role of
the XRCC3 Thr241Met gene polymorphism in lung can-
cer. However, the results of these studies remain incon-
clusive. A single study might not be powered sufficiently
to detect a small effect of the polymorphisms on lung
cancer, particularly in relatively small sample sizes. Fur-
ther, past studies have not controlled for the potential
confounding effect of smoking properly-the main risk
determinant for lung cancer. Various types of study
populations and study designs might also have contribu-
ted to these disparate findings. To clarify the effect of the
XRCC3 Thr241Met gene polymorphism on the risk for
lung cancer, we performed a meta-analysis of all eligible
case–control studies that have been published and con-
ducted the subgroup analysis by stratification according to
the ethnicity source, histological types of lung caner and
smoking status of case and control population.Materials and methods
Publication search
We searched for studies in the PubMed, Embase, Web
of Science, and CNKI (China National Knowledge
Infrastructure) electronic databases to include in this
meta-analysis, using the terms “XRCC3,” “X-ray repair
cross-complementing group 3,” “polymorphism,” and






David-Beabes-2001 USA (Caucasian) 178/453
David-Beabes-2001 USA (Mixed) 153/234
Misra-2001 Finland (Caucasian) 313/306
Wang-2003 USA (Mixed) 112/190
Popanda-2004 Germany (Caucasian) 462/459
Jacobsen-2004 Denmark (Caucasian) 246/269
Harms-2004 USA (Caucasian) 110/119
Matullo-2006 Europe (Caucasian) 116/1094
Zienolddiny-2006 Norway (Caucasian) 220/250
Rky-2006 Sweden (Caucasian) 175/154
Lopez-Cima-2007 Spain (Caucasian) 403/434
Zhang-2007 China (Asian) 291/273
Improta-2008 Italy (Caucasian) 94/121
Xia-2008 China (Asian) 103/139
Osawa K-2010 Japan (Asian) 104/120
Qian B-2011 China (Asian) 581/603
Kiyohara C-2012 Japan (Asian) 462/379
#, the number of the combined C/T and T/T genotypes.applied; no lower date limit was used. The search was
performed without any restrictions on language and was
focused on studies that had been conducted in humans.
We also reviewed the Cochrane Library for relevant arti-
cles. Concurrently, the reference lists of reviews and
retrieved articles were searched manually. Only full-text
articles were included. When the same patient population
appeared in several publications, only the most recent or
complete study was included in this meta-analysis.
Inclusion criteria
For inclusion, the studies must have met the following cri-
teria: they (1) evaluated XRCC3 gene polymorphisms and
lung cancer risk; (2) were case–control studies; (3) supplied
the number of individual genotypes for the XRCC3
Thr241Met gene polymorphisms in lung cancer cases and
controls, respectively; and (4) demonstrated that the distri-
bution of genotypes among controls were in Hardy-
Weinberg equilibrium.
Data extraction
Information was extracted carefully from all eligible publi-
cations independently by 2 authors, based on the inclusion
criteria above. Disagreements were resolved through a dis-
cussion between the 2 authors.
The following data were collected from each study: first
author’s surname, year of publication, ethnicity, total num-
bers of cases and controls, and numbers of cases and con-
trols who harbored the XRCC3 Thr241Met genotypes,ung cancer cases and controls included in this meta-
Lung cancer cases Controls
C/C C/T T/T C/C C/T T/T
76 78 24 175 210 68
90 54 9 136 88 10
160 124 29 149 134 23
69 43# 119 71#
175 201 86 168 222 69
95 123 28 113 113 43
61 37 12 61 49 9
44 56 16 383 544 167
114 90 16 115 111 24
79 96# 56 98#
168 185 50 178 196 60
259 30 2 244 28 1
31 33 30 67 46 8
91 12 0 118 21 0
92 12# 98 22#
521 60 0 533 67 3
352 97 13 295 77 7
Table 2 Summary ORs for various contrasts of XRCC3
Thr241Met gene polymorphisms in this meta-analysis
Subgroup analysis exon7 genotype
Contrast studies OR(95%) Ph
Total T/T vs C/C 17 0.99(0.86-1.15) 0.315
(C/T + T/T) vs C/C 0.95(0.87-1.04) 0.228
Ethnicity
Asian T/T vs C/C 5 0.92(0.71-1.09) 0.216
(C/T + T/T) vs C/C 0.94(0.77-1.15) 0.545
Caucasian T/T vs C/C 10 0.94(0.87-1.13) 0.090
(C/T + T/T) vs C/C 0.95(0.85-1.06) 0.056
Mixed population T/T vs C/C 2 1.04(0.77-1.43) 0.190
(C/T + T/T) vs C/C 1.00(0.73-1.37) 0.823
Histological type
SCC T/T vs C/C 2 0.94(0.78-1.58) 0.164
(C/T + T/T) vs C/C 0.91(0.48-1.74) 0.215
AC T/T vs C/C 3 1.09(0.72-1.38) 0.535
(C/T + T/T) vs C/C 1.05(0.79-1.40) 0.331
Smoking status
Smoker T/T vs C/C 4 0.98(0.72-1.45) 0.006
(C/T + T/T) vs C/C 0.93(0.63-1.37) 0.001
Non-smoker T/T vs C/C 4 0.99(0.78-1.51) 0.230
(C/T + T/T) vs C/C 0.92(0.62-1.37) 0.186
Ph P value of Q-test for heterogeneity test.
Figure 1 Forest plot (random-effects model) of lung cancer risk assoc
versus vs C/C. Each box represents the OR point estimate, and its area is p
represents the overall summary estimate, with CI represented by its width.
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study to request the information. Ethnicities were categor-
ized as Asian, Caucasian, and mixed population. Histo-
logical type of lung cancer was divided to lung squamous
carcinoma (SCC), adenocarcinoma (AC) and small cell
lung cancer (SCLC) in our meta-analysis. The definition of
smoking history is very complicated. The smoking histories
covered different periods if changes in the number of cigar-
ettes smoked per day or type of tobacco products occurred.
According to the general standards, non-smokers were
defined as subjects who had smoked less than 100 cigar-
ettes in their lifetime. Although the precise definition of
never-smoking status varied slightly among the studies, the
smoking status was classified as non-smokers (or never
smoker) and smokers (regardless of the extent of smoking)
in our meta-analysis. We did not require a minimum num-
ber of patients for a study to be included in our meta-
analysis.Statistical analysis
OR (odds ratios) with 95% CIs were used to determine the
strength of association between the XRCC3 Thr241Met
polymorphisms and lung cancer risk.
The pooled ORs for the risk associated with the XRCC3
Thr241Met genotype, the T allele carriers (TC + TT)
versus the wild-type homozygotes (CC), TT versus CC
were calculated, respectively. Subgroup analyses were doneiated with XRCC3 Thr241Met polymorphisms for the (C/T + T/T)
roportional to the weight of the study. The diamond (and broken line)
The unbroken vertical line is set at the null value (OR =1.0).






Lung cancer cases Controls
C/C C/T T/T C/C C/T T/T
Popanda-2004 Germany (Caucasian) AC 71 89 44 168 222 69
Zhang-2007 China (Asian) AC 114 18# 244 29#
SCC 69 10# 244 29#
Osawa K-2010 Japan (Asian) AC 60 8# 98# 22#
SCC 28 3# 98# 22#
#, the number of the combined C/T and T/T genotypes.
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status. Heterogeneity assumptions were assessed by chi-
square-based Q-test [11]. A P value greater than 0.10 for
the Q-test indicated a lack of heterogeneity among the
studies. Thus, the pooled OR estimate of each study was
calculated using the fixed-effects model (the Mantel-
Haenszel method) [12]; otherwise, the random-effects
model (the DerSimonian and Laird method) was used [13].
One-way sensitivity analyses were performed to deter-
mine the stability of the results-each individual study in
the meta-analysis was omitted to reflect the influence of
the individual dataset on the pooled OR [14].
Potential publication biases were estimated by funnel
plot, in which the standard error of log (OR) of each
study was plotted against its log (OR). An asymmetrical
plot suggests a publication bias. Funnel plot asymmetry
was assessed by Egger’s linear regression test, a linear re-
gression approach that measures the funnel plot asym-
metry on a natural logarithm scale of the OR. The
significance of the intercept was determined by t-test, asFigure 2 Forest plot (random-effects model) of lung cancer risk assoc
versus vs C/C stratified by histological types of lung cancer.suggested by Egger (P < 0.05 was considered a statisti-
cally significant publication bias) [15].
All calculations were performed using STATA, version
11.0 (Stata Corporation, College Station, TX).Results
Study characteristics
A total of seventeen publications involving 4123 lung
cancer cases and 5597 controls met the inclusion criteria
and were ultimately analyzed [16-31]. Table 1 presents
the main characteristics of these studies. David-Beabes 's
study [16] sorted the data for Caucasians and Mixed
populations; therefore, each group in the study was con-
sidered separately in the pooled subgroup analyses.
Of the 17 publications, 15 were published in English
and only 2 were written in Chinese. The sample sizes
ranged from 185 to 1210. All cases were histologically
confirmed. The controls were primarily healthy popula-
tions and matched for age, ethnicity, and smoking status.iated with XRCC3 Thr241Met polymorphisms for the (C/T + T/T)







Lung cancer cases Controls
C/C C/T T/T C/C C/T T/T
Wang-2003(36) USA (Mixed) Non-smoking 24 10# 93 67#
Smoking 45 33# 26 4#
Zhang-2007 (47) China (Asian) Non-smoking 73 12# 126 16#
Smoking 110 16# 118 13#
Rky-2006 (35) Sweden (Caucasian) Non-smoking 31 53# 32 42#
Smoking 48 43# 24 56#
Osawa K-2010 Japan (Asian) Non-smoking 28 3# 42 12#
Smoking 63 9# 53 8#
#, the number of the combined C/T and T/T genotypes.
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and 2 mixed populations. All polymorphisms in the con-
trol subjects were in Hardy-Weinberg equilibrium.
Meta-analysis results
Table 2 listed the main results of this meta-analysis. Over-
all, for the T allele carriers (TC + TT) versus homozygote
CC, the pooled OR for all studies combined 4123 cases
and 5597 controls was 0.95 (95% CI = 0.87-1.04 P = 0.228
for heterogeneity) (Figure 1), for TT versus CC the pooled
OR was 0.99 (95% CI = 0.86-1.15 P = 0.315 for heterogen-
eity). For all studies in the meta-analysis, significantly risks
were not found for the T allele carriers (TC + TT) versus
homozygote CC or TT versus CC, and no heterogeneity
was found in all studies.
In the stratified analysis by ethnicity, significantly risks
were not found among Asians for (TC + TT) versus CCFigure 3 Forest plot (random-effects model) of lung cancer risk assoc
versus vs C/C stratified by smoking status of population.(OR = 0.94, 95% CI = 0.77-1.15; P = 0.545 for heterogeneity)
or TT versus CC (OR = 0.92; 95% CI = 0.71-1.09; P =
0.216 for heterogeneity). For Caucasians, significantly
risks were not found for (TC + TT) versus CC (OR =
0.95, 95% CI = 0.85-1.06; P = 0.056 for heterogeneity) or
TT versus CC (OR= 0.94; 95% CI = 0.87-1.13; P = 0.090 for
heterogeneity) .
Three out of 17 studies examined the association of
XRCC3 Thr241Met genotype and the risk of different
histological types of lung cancer including SCC and AC
(Table 3). Among lung SCC, no significantly increased
risks were observed for (TC + TT) versus CC (OR = 0.91,
95% CI = 0.48-1.74; P = 0.215 for heterogeneity) or TT ver-
sus CC (OR = 0.94; 95% CI = 0.78-1.58; P = 0.164 for het-
erogeneity). Among lung AC, no significant associations
were observed for both (TC + TT) versus CC or TT versus
CC (Figure 2).iated with XRCC3 Thr241Met polymorphisms for the (C/T + T/T)
Figure 4 Begg’s funnel plot of XRCC3 Thr241Met
polymorphisms for the (C/T + T/T) versus vs C/C for all studies.
Figure 6 Begg’s funnel plot of XRCC3 Thr241Met
polymorphisms for the (C/T + T/T) versus vs C/C stratified by
smoking status of population.
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cantly risks were found among smokers for (TC + TT) ver-
sus CC (OR= 0.93, 95% CI = 0.63-1.37; P = 0.001 for
heterogeneity) or TT versus CC (OR= 0.98; 95% CI = 0.72-
1.45; P = 0.006 for heterogeneity) (Table 4). In non-smokers,
significantly risks were not found for (TC + TT) versus CC
(OR = 0.92, 95% CI = 0.62-1.37; P = 0.186 for heterogeneity)
or TT versus CC (OR= 0.99; 95% CI = 0.78-1.51; P = 0.230
for heterogeneity) (Figure 3).
Sensitivity analyses
A single study involved in the meta-analysis was deleted
each time to reflect the influence of the individual data
set to the pooled ORs, and the corresponding pooled
Ors were not materially altered (data not shown).
Publication bias
Begg’s funnel plot and Egger’s test were performed to ac-
cess the publication bias of literatures. Evaluation of publi-
cation bias for (TC + TT) versus CC for all studies showedFigure 5 Begg’s funnel plot of XRCC3 Thr241Met
polymorphisms for the (C/T + T/T) versus vs C/C stratified by
histological types of lung cancer.that the Egger test was not significant (p = 0.927). For the
subgroup analyses by histology, the Egger test was also not
significant (p = 0.311) and for the subgroup analyses by
smoking status, the p value of Egger test was 0.552. The
funnel plots (Figures 4, 5, and 6) did not exhibit any patent
asymmetry. These results indicated there was no evidence
of publication bias in our meta-analysis.
Discussion
It is well recognized that there is a range of individual sus-
ceptibility to the same kind of cancer even with identical
environmental exposure. Host factors, including poly-
morphisms of genes involved in carcinogenesis may have
accounted for this difference. Therefore, genetic susceptibil-
ity to cancer has been a research focus in scientific commu-
nity. Recently, genetic variants of the DNA repair genes in
the etiology of several cancers have drawn increasing atten-
tion. As it is known that individual studies with a small
sample size may have not enough statistical power to detect
a small risk factor, in this meta-analysis, we involved a total
of 4123 lung cancer cases and 5597 controls and explored
the association between the XRCC3 Thr241Met poly-
morphisms and lung cancer risk. Our results indicated that
XRCC3 Thr241Met polymorphism was not significantly
associated with the susceptibility to lung cancer. Addition-
ally, no significant associations were also found in the strati-
fied analysis by ethnicity, histological types or smoking
status.
Population stratification is a troubling issue and can lead
to spurious evidence on the association between markers
and a disease, implicating the disparate effects of environ-
ment and ethnic differences on genetic background [32].
In this meta-analysis, ethnicity stratification of differences
between Asians and Caucasians was not found. Tobacco
smoke contains many known carcinogens and pro-carci-
nogens, such as benzopyrene and nitrosamine. Our meta-
analysis results showed no significantly risks were found
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isms and lung cancer risk in smokers or non-smokers.
There were only small number of studies examined the
association between the XRCC3 Thr241Met gene poly-
morphism and lung cancer risk in smokers or non-
smokers; moreover, the p value of Q test for heterogeneity
test was significant. Considering the limited studies and
P value of Q-test for heterogeneity test included in this
meta-analysis, our results should be interpreted with
caution.
When subgroup analyses by pathological type were
considered, no significant associations were also found
in lung AC subgroup or SCC subgroup. There are grow-
ing biological and epidemiological data to suggest that dif-
ferent lung cancer pathological subtypes, particularly the
two most common, were distinct etiological entities that
should be analyzed separately [33]. In the process of histo-
logical differentiation of lung cancer, XRCC3 Thr241Met
polymorphisms may be not independent factor.
In our study, the three studies [17,19,25] accounted
for 32.7% weight of all 17 studies. Popanda et al. [19]
study accounted for 12.2% weight and included 921
cases, Lopez-Cima et al. [25] study accounted for 11.4%
and included 837 cases, Misra et al. [17] study accounted
for 9% and included 619 cases. The results of these three
studies were consistent, with no significant association
between the XRCC3Thr241 Met polymorphism and lung
cancer risk. Moreover, the pooled OR of our meta-
analysis was coincident with these three studies.
Improta G et al. [27] conducted a case–control study to
examine the role of XRCC3 and XRCC1 genetic poly-
morphisms in the context of lung and colorectal cancer
risk for Southern Italian population. As a result, the sig-
nificant association was found between the XRCC3
Thr241Met polymorphisms and colorectal and lung can-
cer, more importantly, the risk of lung cancer of XRCC3
Thr241Met polymorphisms was relatively high (OR = 2.52,
95%: 1.44-4.41). In Wang et al. study [18], they found that
no significant association between the XRCC3Thr241 Met
polymorphism (OR = 1.04; 95% CI = 0.65–1.56) and lung
cancer risk was shown. However, a significantly increased
risk for lung cancer (OR = 4.77; 95% CI = 1.52 –14.97) was
evident in smokers with the variant T-allele genotypes.
Furthermore, a joint effect of the T-allele and heavy smok-
ing was observed (OR = 37.31; 95% CI = 11.43–121.72). In
our meta-analysis, for all studies the pooled OR was 0.95
(95% CI = 0.87-1.04), however the OR of the above-two
studies was relative higher, thus they shown on the outlier
of the Figures 1 and 3.
Some limitations of this meta-analysis should be
acknowledged. First, heterogeneity can interfere with the
interpretation of the results of a meta-analysis. Although
we minimized this likelihood by performing a careful
search of published studies, using explicit criteria for astudy's inclusion and performing strict data extraction
and analysis, significant interstudy heterogeneity never-
theless existed in nearly every comparison. The presence
of heterogeneity can result from differences in the selec-
tion of controls, age distribution, and prevalence of life-
style factors. Although most controls were selected from
healthy populations, some studies had selected controls
among friends or family members of lung cancer
patients or patients with other diseases. Further, only
published studies were included in this meta-analysis.
The presence of publication bias indicates that non-
significant or negative findings might be unpublished.
Finally, our results were based on unadjusted estimates;
a more precise analysis should have been conducted if
individual data were available, which would have allowed
us to adjust using other covariates, including age,
ethnicity, family history, environmental factors, and life-
style [34].
Despite these limitations, this meta-analysis suggests
that the XRCC3 Thr241Met polymorphisms are not
associated with lung cancer risk stratified analysis by
ethnicity, histology and smoking status. However, it is
necessary to conduct large sample studies using standar-
dized unbiased genotyping methods and well-matched
controls.
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